What is the current valuation of the Japan neurodegenerative disease market?

The market valuation was $5.12 Billion in 2024. Read More

What is the projected market size for the Japan neurodegenerative disease market by 2035?

The market is projected to reach $11.46 Billion by 2035. Read More

What is the expected CAGR for the Japan neurodegenerative disease market during the forecast period 2025 - 2035?

The expected CAGR is 7.59% during the forecast period. Read More

Which companies are the key players in the Japan neurodegenerative disease market?

Key players include Biogen, Eli Lilly, Roche, Novartis, AstraZeneca, Merck & Co, Amgen, Sanofi, and Pfizer. Read More

What are the market segments for neurodegenerative diseases in Japan?

The market segments include Disease Type, Diagnosis Method, Treatment Type, and Route of Administration. Read More

What was the market valuation for Alzheimer's Disease in 2024?

The market valuation for Alzheimer's Disease was $1.5 Billion in 2024. Read More

What is the projected market size for Parkinson's Disease by 2035?

The projected market size for Parkinson's Disease is $2.5 Billion by 2035. Read More

How much is the market for neurological examination expected to grow by 2035?

The market for neurological examination is expected to grow to $3.45 Billion by 2035. Read More

What is the projected valuation for medication in the treatment of neurodegenerative diseases by 2035?

The projected valuation for medication is $5.67 Billion by 2035. Read More

What are the expected market values for injectable treatments by 2035?

The expected market value for injectable treatments is $2.85 Billion by 2035. Read More

Japan Neurodegenerative Disease Market

ID: MRFR/MED/50853-HCR

200 Pages

Vikita Thakur

Last Updated: February 06, 2026

Japan Neurodegenerative Disease Market Research Report: Size, Share, Trend Analysis By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) - Growth Outlook & Industry Forecast 2025 To 2035

Japan Neurodegenerative Disease Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Disease Type (USD Billion)
  1. 4.1.1 Alzheimer's Disease
  2. 4.1.2 Parkinson's Disease
  3. 4.1.3 Multiple Sclerosis
  4. 4.1.4 Amyotrophic Lateral Sclerosis
  5. 4.1.5 Huntington's Disease
2. 4.2 Industrial Automation & Equipment, BY Diagnosis Method (USD Billion)
  1. 4.2.1 Neurological Examination
  2. 4.2.2 Imaging Techniques
  3. 4.2.3 Cerebrospinal Fluid Analysis
  4. 4.2.4 Electrophysiological Tests
3. 4.3 Industrial Automation & Equipment, BY Treatment Type (USD Billion)
  1. 4.3.1 Medication
  2. 4.3.2 Therapy
  3. 4.3.3 Rehabilitation
  4. 4.3.4 Surgical Interventions
4. 4.4 Industrial Automation & Equipment, BY Route of Administration (USD Billion)
  1. 4.4.1 Oral
  2. 4.4.2 Injectable
  3. 4.4.3 Intravenous
  4. 4.4.4 Transdermal
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Biogen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 JAPAN MARKET ANALYSIS BY DISEASE TYPE
3. 6.3 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD
4. 6.4 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE TYPE, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Japan Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Disease Type (USD Billion, 2025-2035)

Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Huntington's Disease

Industrial Automation & Equipment By Diagnosis Method (USD Billion, 2025-2035)

Neurological Examination
Imaging Techniques
Cerebrospinal Fluid Analysis
Electrophysiological Tests

Industrial Automation & Equipment By Treatment Type (USD Billion, 2025-2035)

Medication
Therapy
Rehabilitation
Surgical Interventions

Industrial Automation & Equipment By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Intravenous
Transdermal

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”